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Abstract
Introduction: Acid phosphatase locus 1 (ACP1) encodes a low molecular weight phosphotyrosine phosphatase
implicated in a number of different biological functions in the cell. The aim of this study was to determine the
contribution of ACP1 polymorphisms to susceptibility to rheumatoid arthritis (RA), as well as the potential
contribution of these polymorphisms to the increased risk of cardiovascular disease (CV) observed in RA patients.
Methods: A set of 1,603 Spanish RA patients and 1,877 healthy controls were included in the study. Information
related to the presence/absence of CV events was obtained from 1,284 of these participants. All individuals were
genotyped for four ACP1 single-nucleotide polymorphisms (SNPs), rs10167992, rs11553742, rs7576247, and
rs3828329, using a predesigned TaqMan SNP genotyping assay. Classical ACP1 alleles (*A, *B and *C) were imputed
with SNP data.
Results: No association between ACP1 gene polymorphisms and susceptibility to RA was observed. However,
when RA patients were stratified according to the presence or absence of CV events, an association between
rs11553742*T and CV events was found (P = 0.012, odds ratio (OR) = 2.62 (1.24 to 5.53)). Likewise, the ACP1*C
allele showed evidence of association with CV events in patients with RA (P = 0.024, OR = 2.43).
Conclusions: Our data show that the ACP1*C allele influences the risk of CV events in patients with RA.
Introduction
Rheumatoid arthritis (RA) is a complex polygenic auto-
immune inflammatory disease characterized by persistent
synovitis and joint damage. Several genetic polymorph-
isms, such as HLA-DRB1, PTPN22, STAT4, TRAF1/C5
and TNFAIP3, have been implicated in the susceptibility
to RA [1]. On the other hand, increased cardiovascular
(CV) mortality is observed in patients with RA. This is
the result of accelerated atherogenesis [2-4].
Acid phosphatase locus 1( ACP1) is a gene located on
chromosome 2p25 that encodes a low molecular weight
phosphotyrosine phosphatase (LMW-PTP), which pre-
sents two main enzymatic activities: phosphoprotein tyr-
osine phosphatase and flavin mononucleotide
phosphatase [5]. Two different isoenzymes of LMW-
PTP have been described: ‘fast’ (also noted as ACP1-F
(fast), isoform 1, IF1, HCPTP-A) and ‘slow’ (also noted
as ACP1-S(slow), isoform 2, IF2, HCPTP-B), that arise
through alternative splicing mechanisms, in which either
exon 3 or exon 4 is excised and the other retained
respectively [5,6]. These two LMW-PTP isoenzymes
have different molecular and catalytic properties, sug-
gesting that they may be implicated in different biologi-
cal functions in the cell [5,7]. In Caucasian populations
there are three common codominant alleles of ACP1,
ACP1*A, ACP1*B, ACP1*C. ACP1 alleles differ on sin-
gle-nucleotide polymorphisms (SNPs), which affect both
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forms F/S, being the ratio F/S 2:1 in ACP1*A, 4:1 in
ACP1*B and 1:4 in ACP1*C [5,7,8].
LMW-PTP is considered to play a key role as regula-
tor of signaling pathways in receptor-stimulated immune
cells [9]. LMW-PTP has also been involved in the regu-
lation of many growth factors such as platelet-derived
growth factor receptor (PDGFR) [10], fibroblast growth
factor receptor (FGFR) [11], insulin receptor (IR) [12,13]
and EphA2 receptor, a ligand that binds to the Ephrin
family of signaling molecules [14]. LMW-PTP has also
been implicated in the regulation of ZAP70 Kinase (ζ-
chain- associated protein kinase of 70 kDa) [15] playing
a role in T-cell development and lymphocyte activation,
enhancing signaling from the T cell antigen receptor
[15]. Additionally, LMW-PTP has been found to be a
key mediator in the integrin signaling during cellular
adhesion [9].
Allelic polymorphisms of the ACP1 gene have been
associated with susceptibility to several human diseases,
including inflammatory and autoimmune diseases [5,16].
Interestingly, the ACP1 gene was also associated with
susceptibility to coronary atherosclerotic artery disease
(CAD) [17].
Taking into account the possible influence that ACP1
may have in the susceptibility to immune-mediated dis-
orders and in the pathogenesis of the CV disease, in the
present study we aimed to investigate the possible asso-
ciation of ACP1 alleles with the susceptibility to RA as
well as whether ACP1 gene polymorphism may contri-
bute to the increased risk of CV complications observed
in patients with RA.
Materials and methods
Material
A set of 1,603 RA Spanish patients and 1,877 healthy
individuals were included in the present study. Blood
samples were obtained from RA patients recruited from
the Hospital Xeral-Calde (Lugo), Hospital Universitario
Marqués de Valdecilla (Santander), Hospital Universi-
tario Bellvitge (Barcelona), and Hospital La Paz, Hospital
de La Princesa and Hospital Clínico San Carlos
(Madrid). All the patients fulfilled the 1987 American
College of Rheumatology (ACR) criteria for the classifi-
cation of RA [18].
Information related to the presence or absence of CV
events was obtained in 1,284 RA patients (80.1%, 1284/
1,603). Among them, 229 experienced CV events
(17.8%, 229/1,284). Information on traditional CV risk
factors was also collected.
Clinical features of the whole series of 1,603 RA
patients are shown in Table 1.
A CV event was considered to be present if the
patient had ischemic heart disease, heart failure, a
cerebrovascular accident or peripheral artheriopathy.
Clinical definitions for CV events and classic CV risk
factors were established as previously described [4,19].
The study was approved by local ethics committees
from all the participating centers and all subjects pro-
vided informed consent according to the Declaration of
Helsinki.
SNPs selection and genotyping
DNA from patients and controls was obtained using
standard methods. We selected four ACP1 SNPs for the
present study. rs11553742 and rs7576247 were selected
because of their ability to tag classical ACP1 alleles (that
is, ACP1*A, ACP1*B, ACP1*C) [5]. rs11553742 is a
synonymous polymorphism located in the codon 44
(exon 3) and rs7576247 encodes an aminoacid change
in the codon 105 (exon 6) from arginine, present in
ACP1*A allele, to glutamine in ACP1*B and *C alleles.
Hence, ACP1*A allele differs from ACP1*C allele in two
base substitutions in those positions, so the CG allele
combination is responsible for the ACP1*A allele and
TA for the ACP1*C allele. In addition, ACP1*B allele is
defined as not *A, not *C, that is, for the allelic combi-
nation CA. Another two polymorphisms, rs10167992
and rs3828329, were also selected because they showed
association with quantitative traits related to type 2 dia-
betes mellitus [17]. All SNPs were genotyped with Taq-
Man SNP genotyping assays in a 7900 HT Real-Time
Table 1 Demographic characteristics of the patients with
rheumatoid arthritis included in the study
Clinical feature % (n/N)
Patients 1,603
Main characteristics
Age at disease onset (years, means ± SE) 54.1 ± 14.8
Follow up (years, means ± SE) 11 ± 7.5
Female 73.5
Rheumatoid factor positive 70.3 (996/1,417)
Shared Epitope positive 63.7 (592/930)
Anti-CCP antibodies positive 58.1 (652/1,123)
Cardiovascular risk factors
Hypertension 39.4 (516/1,310)
Diabetes mellitus 13.2 (171/1,300)
Dyslipidemia 41.3 (540/1,307)
Obesity 12.4 (142/1,146)
Smoking habit 24.0 (303/1,261)
Patients with cardiovascular events 17.8 (229/1,284)
Ischemic heart disease 9.5 (122/1,284)
Heart failure 4.8 (62/1,284)
Cerebrovascular accidents 4.6 (59/1,284)
Peripheral arteriopathy 1.9 (25/1,284)
SE, Standard error
Anti-CCP antibodies, anti-cyclic citrullinated peptide antibodies
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Page 2 of 6polymerase chain reaction (PCR) system, according to
the conditions recommended by the manufacturer
(Applied Biosystems, Foster City, CA, USA). All samples
were genotyped at the same center.
Statistical analysis
Controls were tested for significant differences in their
genotype distribution and Hardy-Weinberg equilibrium
(HWE) theoretical distribution by means of a c
2 test.
The case-control association study was performed by 2
× 2 contingency tables with c
2 to obtain P-values, odds
ratios (OR) and 95% confidence intervals (CI), according
to Woolf’s methods. The same procedure was applied in
the subgroups stratified according to the presence or
absence of anti-cyclic citrullinated peptide antibodies
(ACPA). Association analysis for CV events in RA
patients was performed via multiple logistic regression;
estimates were adjusted for age at the time of disease
diagnosis, gender, rheumatoid shared epitope status and
traditional CV risk factors (hypertension, diabetes melli-
tus, dyslipidemia, obesity and smoking habit) as poten-
tial confounders.
All P-values < 0.05 were considered as statistically sig-
nificant. All statistical analyses were carried out with
Plink [20] and haplotype analysis with Haploview [21].
The estimation of the statistical power of the study
to detect an effect of a polymorphism in disease sus-
ceptibility was performed using the CaTS Power Cal-
culator software (Center for Statistical Genetics,
University of Michigan, Michigan, USA) [22]. The
study had between 98 and 100% power to detect the
relative risk, with an OR of 1.50 at the 5% significance
level, assuming a RA Spanish prevalence of this disease
of 0.5% and considering a minor allele frequency
(MAF) between 0.05 and 0.25 respectively. Under the
same conditions described above, our study of the risk
of CV events in RA patients had a statistical power
from 95% when the disease allele frequency was 0.25
to 42% for an allele frequency of 0.05.
Results
ACP1 polymorphisms in RA patients and controls
All genetic variants analyzed did not deviate significantly
from the HWE, and the genotyping success call rate was
90%. After comparing RA patients and healthy indivi-
duals, no significant differences in the ACP1 allele and
genotype frequencies were found (Additional file 1). We
also assessed the possible influence of these ACP1 poly-
morphisms in the presence and absence of ACPA; how-
ever, no evidence of association was observed. In
addition, we performed the analysis of allelic combina-
tions to investigate the possible association of each of
these three codominant ACP1 alleles (*A, *B and *C)
with RA but no significant association was found. Again,
no association was observed for ACP1 alleles when RA
patients were stratified according to ACPA (Additional
file 2).
ACP1 polymorphisms and CV risk in RA patients
We further investigated the possible influence of ACP1
polymorphisms in the risk of CV events in RA patients.
Of the 1,284 RA patients for whom information on pre-
sence or absence of CV disease was available, 229 had
CV events (17.8%). Table 2 describes the distribution of
ACP1 p o l y m o r p h i s m si nR Ap a t i e n t sw i t ha n dw i t h o u t
CV events. After adjusting for classical CV risk factors,
evidence of association of rs11553742*T with the risk of
CV events was observed (P-adj = 0.012, OR = 2.62 (1.24
to 5.53)).
The potential influence of ACP1*A, *B and *C alleles
in the CV risk of RA patients was also analyzed (Table
3). We found that the ACP1*C allele was significantly
associated with CV risk in RA patients after correction
for classic CV risk factors (P-adj = 0.024, OR = 2.43).
As expected, ACP1*C allele (TA) included the minor
rs11553742*T allele, which was also found to be a risk
factor for the CV events in RA patients (see Table 2).
In contrast, ACP1*A allele (CG), which was the oppo-
site allelic combination of ACP*C, showed a trend for
Table 2 Differences between RA patients with and without CV events according to ACP1 polymorphisms
Change Genotype, no. (frequency) Minor allele, Allele test
SNP 1/2 Samples Set N 1/1 1/2 2/2 no. (frequency) P-adj* OR (95% CI)*
rs10167992 C/T RA with CV 215 171 (0.826) 35 (0.169) 1 (0.005) 37 (0.089) 0.321 0.72 (0.38 to 1.37)
RA without CV 965 768 (0.799) 168 (0.175) 13 (0.014) 194 (0.102)
rs11553742 C/T RA with CV 221 200 (0.966) 21 (0.101) 0 (0.000) 21 (0.048) 0.012 2.62 (1.24 to 5.53)
RA without CV 1,015 932 (0.970) 78 (0.081) 3 (0.003) 84 (0.041)
rs7576247 A/G RA with CV 207 112 (0.541) 76 (0.367) 18 (0.087) 112 (0.272) 0.203 0.76 (0.50 to 1.16)
RA without CV 961 498 (0.518) 388 (0.404) 75 (0.078) 538 (0.280)
rs3828329 C/T RA with CV 221 88 (0.425) 103 (0.498) 28 (0.135) 641 (0.319) 0.079 1.38 (0.96 to 1.97)
RA without CV 1,015 482 (0.502) 403 (0.419) 119 (0.124) 159 (0.363)
CV, cardiovascular; RA, rheumatoid arthritis
* multiple regression adjusted by age at diagnosis of the disease, gender, shared epitope status and traditional CV risk factors, that is, hypertension, diabetes
mellitus, dyslipidemia, obesity and smoking habit, as potential confounders.
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patients, although no statistically significant association
was achieved (P-adj = 0.217, OR = 0.76).
Discussion
Since the association of ACP1 gene with autoimmunity
has previously been described [5], in the present study
we sought to investigate the possible association of
ACP1 polymorphisms with RA. Furthermore, taking into
account that this gene has been involved in the suscept-
ibility to CAD [17], we also assessed whether ACP1 var-
iations could be involved in the risk of CV events in
patients with RA. Our result revealed that ACP1 poly-
morphisms do not influence the susceptibility to RA.
However, these polymorphisms seem to influence the
risk of CV events in these patients. In this regard, both
rs11553742*T and ACP1*C alleles increased the risk of
CV complications in patients with RA. Interestingly,
rs11553742*T has been observed to decrease the F/S
ratio of the LMW-PTP isoenzymes [5]; in this regard
the ACP1*C allele, carrier of the minor allele of
rs11553742, was found to produce a major amount of S
isoforms and is also associated with the highest total
LMW-PTP activity [8,23].
Our results are in accordance with the findings by
Banci et al. [17], who observed that high S isoform gen-
otypes were associated with increased risk to develop
CAD. Moreover, patients with hypertrophic cardiomyo-
pathy, an autosomal dominant disease, were found to
have the highest frequencies for ACP1*C allele and
showed a linear relationship between maximum wall
thickness and the amount of total LMW-PTP activity
[16].
The effect of the ACP1*C allele in the development of
CV events could be explained by its possible role in the
regulation of the energy metabolism and oxidative stress
through its flavin mononucleotide phosphatase activity
[8]. With respect to this, a negative interaction between
LMW-PTP and the enzyme glutathione reducatase
(GSR), which affects the cellular concentration of their
cofactor flavin adenosine dinucleotide (FAD), has been
described [8]. GSR is a flavoenzyme involved in the cel-
lular antioxidant mechanism that reduces oxidized glu-
tathione disulfide (GSSG) to the sulfhydryl form
glutathione (GSH) that is an important cellular antioxi-
dant. Low LMW-PTP activity increases the levels of
cofactor flavin adenine dinucleotide (FAD) in the cytosol
leading to increased activity of GSR; while higher LMW-
PTP activity yields low GSR activity. Accordingly, low
activity of GSR has also been found to be significantly
associated with hypertension [24], and it has also been
considered to be a risk factor for CV by influencing
cholesterol levels [25]. Furthermore, Bottini et al.[ 2 6 ]
reported that the ACP1*A allele, the opposite allelic
combination of ACP*C, is a protective factor for hyper-
triglyceridemia and hypercholesterolemia in obese
women.
RA is a complex polygenic disease and, besides the
association of HLA-DRB1*04 shared epitope alleles with
CV disease [4,27], recent reports have also emphasized
the potential implication of other gene polymorphisms
in the increased risk of CV events observed in patients
with RA. In this regard, interactions between NOS gene
polymorphisms and HLA-DRB1*04 shared epitope alleles
seem to confer an increased risk of developing CV
events in these patients [28]. Also, the A1298C poly-
morphism in the MTHFR gene was found to predispose
to CV risk in RA [29]. More recently, an association of
the TNFA rs1800629 gene polymorphism with predispo-
sition to CV complications in RA patients carrying the
rheumatoid shared epitope was also described [30].
Conclusions
Our data show for first time the association of the
ACP1*C allele with increased susceptibility to CV events
in patients with RA. This effect may be based on the
major production of the S isoform of LMW-PTP by this
allele, which may influence the regulation of energy
metabolism and the response to oxidative stress.
Additional material
Additional file 1: Genotype and allele distribution of ACP1
polymorphisms in Spanish RA patients and healthy subjects.
Supplementary table S1 shows the genotype and allele frequencies of
ACP1 polymorphisms in Spanish RA patients and healthy controls. That
table also shows the lack of association among cases and controls.
Additional file 2: Distribution of ACP1 alleles in Spanish RA patients
and healthy controls. Supplementary table S2 shows the frequencies of
ACP1 alleles in Spanish RA patients and individuals controls. No
association was observed.
Abbreviations
ACP1: acid phosphatase locus 1; ACPA: anti-cyclic citrullinated peptide
antibodies; ACR: American College of Rheumatology; CAD: coronary
atherosclerotic artery disease; CI: confidence intervals; CV: cardiovascular;
Table 3 Distribution of ACP1 alleles in RA patients with
and without CV events
Haploype, no. (frequency)
ACP1 allele Haplotype RA with CV RA without CV P-adj* OR*
ACP1*A CG 110 (0.276) 525 (0.281) 0.217 0.76
ACP1*B CA 270 (0.678) 1,263 (0.676) 0.859 1.04
ACP1*C TA 18 (0.045) 80 (0.043) 0.024 2.43
CV, cardiovascular; RA, rheumatoid arthritis The order of the SNPs is
rs11553742|rs7576247.
* multiple regression adjusted by age at diagnosis of the disease, gender,
shared epitope status, hypertension, diabetes mellitus, dyslipidemia, obesity
and smoking habit.
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Page 4 of 6FAD: flavin adenosine dinucleotide; FGFR: fibroblast growth factor receptor;
GSH: glutathione; GSR: glutathione reducatase; GSSR: glutathione disulfide;
HWE: Hardy-Weinberg equilibrium; IR: insulin receptor; LMW-PTP: low
molecular weight phosphotyrosine phosphatase; MAF: minor allele
frequency; OR: Odds ratio; PCR: polymerase chain reaction; PDGFR: platelet-
derived growth factor receptor; RA: rheumatoid arthritis; SNP: single-
nucleotide polymorphism.
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